Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Mohit Sodhi MSc, MD[1,2], Ramin Rezaeianzadeh BSc[3], Abbas Kezouh PhD[4], Connor Frey BSc[5],

Mahyar Etminan PharmD MSc[1,2]

[1]Epilytics, Vancouver, British Columbia, Canada

[2]Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver,

Canada

[3]Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

[4] StatExpert Ltd, Laval, Quebec, Canada

[5]MD Undergraduate Program, Faculty of Medicine, University of British Columbia, Vancouver,

Canada

Corresponding author:

Mahyar Etminan, PharmD, MSc.

Faculty of Medicine | University of British Columbia

Departments of Ophthalmology and Visual Sciences, Pharmacology and Medicine | The Eye Care

Center

Room 323-2550 Willow Street, Vancouver BC, V5Z 3N9

Phone 778-846-9604 | Fax 604-875-4663

etminanm@mail.ubc.ca

Word count (text): 568

Keywords: GLP-1 agonist; weight loss; hair loss; drug safety.

ABSTRACT

GLP-1 (glucagon-like peptide-1) agonists including semaglutide and liraglutide are possibly the most prescribed medications in the world. Many recent studies have quantified their adverse events with a focus on gastrointestinal adverse events. However, no large epidemiologic study has investigated the risk of hair loss with these medications. We conducted a retrospective cohort study using a large health claims database to investigate this risk. Using a random sample of 16 million patients, we identified new users of semaglutide or liraglutide and an active comparator bupropion-naltrexone. We excluded those with a diagnosis of diabetes or use of antihyperglycemics prior to cohort entry. Cohort members were followed from the first date of a study drug prescription to the diagnosis of alopecia areata. We adjusted for age, sex, geographic location, depression, steroid use, hypothyroidism, polycystic ovary syndrome, and anemia. Our cohort included 926 semaglutide users, 17,898 liraglutide users, and 1,348 users of bupropion-naltrexone. We found that compared to bupropion-naltrexone, the crude hazard ratio and adjusted hazard ratio for alopecia areata for semaglutide or liraglutide use was 1.73 (95% confidence interval: 1.00-3.01) and 2.09 (95% confidence interval: 1.20-3.65) respectively. Our results demonstrate an increased risk of alopecia areata with GLP-1 agonists. Future studies are required to ascertain the association between GLP-1 agonists and alopecia areata.

INTRODUCTION

Glucagon-like peptide-1 (GLP-1) agonists are one of the most prescribed classes of drugs worldwide and are indicated for the treatment of diabetes or obesity. Approximately 1 in 8 people in the USA have used GLP-1 agonists[1]. Several studies have addressed the adverse events profiles of these drugs but have focussed mainly on the gastrointestinal adverse events[2]. Anecdotal data has alluded to alopecia areata (AA) as another adverse event associated with this class of drug. Data from the Food and Drug Administration (FDA) have reported more hair loss events with GLP-1 agonists compared to other antidiabetics[3]. However, to date, no epidemiologic study has examined this association in a real life setting especially in those taking GLP-1 agonists purely for weight loss.

METHODS

Our data included a random sample of 16 million patients (2006-2020) from the IQVIA PharMetrics® Plus for Academics. It captures 93% of all outpatient prescriptions and physician diagnoses in the US through the *International Classification of Diseases, Ninth and Tenth Revisions (ICD-9 or 10).* We included new users of semaglutide or liraglutide, 2 main GLP-1 agonists, and the active comparator bupropion-naltrexone, a weight loss agent unrelated to GLP-1 agonists. Those with a diagnosis of diabetes or use of an antidiabetic before cohort entry were excluded. This cohort was previously described by Sodhi[2]. Cohort members were followed from the first date of a study drug prescription to the first diagnosis of AA defined by the first ICD-9 or ICD-10 code for the condition or termination of follow up. A Cox regression model was used to compute hazard ratios (HRs) that adjusted for age, sex, geographic location, depression, anemia, hypothyroidism, polycystic ovary syndrome, and use of oral corticosteroids. All analyses were

performed using SAS version 9.4. Ethics approval was obtained by the University of British

Columbia's clinical research ethics board with a waiver of informed consent.

RESULTS

Our cohort included 926 semaglutide users, 17,898 liraglutide users, and 1,348 users of

bupropion-naltrexone (Table 1). Bupropion-naltrexone users were older than GLP-1 agonist users.

Incidence rates for alopecia areata for semaglutide, liraglutide, and bupropion-naltrexone users

was 6/10,000, 77/10,000, and 46/10,000 person-years respectively (Table 1). The crude and

adjusted hazard ratio for AA for semaglutide or liraglutide compared to bupropion-naltrexone

were 1.73 (95% CI: 1.00-3.01) and 2.09 (95%CI: 1.20-3.65) respectively. These estimates were

similar in magnitude indicating minimal measured confounding.

DISCUSSION

This study shows that AA is associated with GLP-1 agonist use compared to users of bupropion-

naltrexone. Our results are in line with a clinical trial data for Wegovy® that also showed an

elevated risk of hair loss (RR=2.38, 95% 1.41-4.0) compared to placebo users[4]. Although not

fully elucidated, it is postulated that AA secondary to GLP-1 agonists might be due to the

physiological stress rapid weight loss can induce, causing telogen effluvium and leading to

increased hair shedding[5]. This may be more prominent with GLP-1 agonists compared to other

antidiabetics as they are known to decrease weight more rapidly than bupropion-naltrexone, thus

inducing greater physiological stress on the body and thus potentially greater hair loss[6]. It is also

possible that due to GLP-1 agonists' appetite suppressive properties, patients have less food intake

potentially causing nutrient deficiencies. Those considering using GLP-1 agonists strictly for

weight loss might want to factor in hair loss as a possible limitation of these drugs.

Limitations of our study include lack of data on GLP-1 agonists' indication. Future studies are required to ascertain the association between GLP-1 agonists and alopecia areata.

Author Contributions: Dr. Etminan had full access to all the data and takes responsibility for the integrity and accuracy of the data.

Concept and design: Etminan and Sodhi

Acquisition, analysis, or interpretation of data: All authors

Drafting of the manuscript: Etminan, Sodhi, Rezaeianzadeh, and Frey

Critical revision of the manuscript for important intellectual content: All authors

Statistical analysis: Kezouh

Obtained funding: Etminan

Supervision: Etminan

Conflict of Interest Disclosures: Dr. Etminan has previously consulted on the Ozempic litigation.

Funding/Support: This study was funded by internal research funds from the Department of Ophthalmology and Visual Sciences, University of British Columbia.

Role of the Funder/Sponsor: The funding organization did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Agreement: We will not be sharing the data, however we are open to answering any questions regarding collection, management, analysis, or interpretation of our data source.

REFERENCES

1. Harris E. Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable. *JAMA*. 2024;332(1):8.

2. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. *JAMA*. 2023;330(18):1795-1797.

3. Nakhla M, Nair A, Balani P, et al. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study [published online September 12, 2024]. *Cardiovasc Drugs Ther*. doi: 10.1007/s10557-024-07613-w.

4. Novo Nordisk. Wegovy ® Product Monograph. https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Wegovy-product-monograph.pdf . Accessed February 15, 2024.

5. Desai DD, Sikora M, Nohria A, et al. GLP-1 agonists and hair loss: a call for further investigation. *Int J Dermatol*. 2024;63(9):1128-1130.

6. Sherman MM, Ungureanu S, Rey JA. Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. *P T*. 2016;41(3):164-72.

Table 1. Characteristics of semaglutide, liraglutide, and bupropion-naltrexone users.

	Semaglutide	Liraglutide	Bupropion-Naltrexone
Number	1,926	17,898	1,348
Age (in years, mean ± STD)	54.8 ± 117	53.7 ± 12.2	45.9 ± 11.3
Sex (%)			

Male	46.7	44.0	18.6
Female	53.3	56.0	81.4
Median Follow-up in Years (interquartile range)	0.3-0.7	0.9-1.8	0.8-1.8
Incidence*	6.4	76.8	46.2
Covariates (%):			
Depression	20.5	11.4	14.1
Hypothyroidism	26.3	20.8	23.4
Oral Steroids	5.1	3.8	5.7
Polycystic Ovary Syndrome	5.1	3.8	5.7
Anemia	11.3	9.5	10.0
Region (in the USA):			
Northeast	13.1	22.4	17.8
Southeast	32.0	23.5	32.2
Midwest	29.6	27.1	22.8
Southwest	11.4	9.9	14.2
West	13.6	15.0	12.8
Unknown	0.3	2.3	0.3

*Incidence is rate per 10,000 person-years.